UNSPSC 51333707: Prothipendyl hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C16H19N3S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7610629RVH, chemically known as 10h-pyrido(3,2-b)(1,4)benzothiazine, 10-(3-(dimethylamino)propyl)-, monohydrochloride but more generally known as prothipendyl hydrochloride, which bears US NIH Compound Identifier 14669. European Medicines Agency schedules Prothipendyl hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04111MIG.

UNSPSC 51333707 Prothipendyl hydrochloride is a Commodity code that in practice captures state and local procurement of pharmaceutical products, including naloxone, generic multi-source drugs, and over-the-counter products for public health and community benefit programs. State and local health departments, cooperative purchasing alliances, and county health authorities are the primary issuing bodies, with activity driven by opioid-response initiatives, pharmacy benefit management, and generic medication supply agreements that serve multiple jurisdictions through centralized contracting vehicles.

Recent solicitations show two distinct procurement patterns. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly delivery to the county community health building and a two-year initial term plus one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract term effective July 1, 2026; vendors must maintain relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as preliminary market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, gathering vendor capabilities around direct contracting with self-insured plans and manufacturers outside traditional pharmacy benefit manager arrangements. Activity concentrates in Florida, Texas, and the Upper Midwest (Minnesota, Oregon), with cooperative purchasing vehicles extending reach across multiple states.